CPE | Pneumonia | COPD | CPE + COPD | Pneumonia + COPD | Hypercapnic pneumonia + COPD | Ob-hypoven | |||||
---|---|---|---|---|---|---|---|---|---|---|---|
Total | Hypercapnic | Non-hypercapnic | Total | Hypercapnic | Non-hypercapnic | ||||||
APACHE, Acute Physiology and Chronic Health Evaluation; CPE, cardiogenic pulmonary oedema; COPD, chronic obstructive pulmonary disease; ob-hypoven, obesity-hypoventilation decompensation; NA, not applicable. | |||||||||||
*number (%); †trials with available arterial blood gas data: CPE 63/70, pneumonia 23/27, pneumonia + COPD 20/21. | |||||||||||
Number trials | 70* | 45 | 18 | 27* | 12 | 11 | 39 | 11 | 21* | 18 | 6 |
Number patients | 69 | 44 | 18 | 26 | 12 | 11 | 37 | 11 | 20 | 17 | 6 |
Successes† | 55/70 (78.6%) | 38/45 (84.4%) | 13/18 (72.2%) | 10/27 (37%) | 5/12 (41.6%) | 4/11 (36.4%) | 25/39 (64.1%) | 6/11 (54.5%) | 6/21 (28.6%) | 5/18 (27.8%) | 6/6 (100%) |
Actual mortality† | 16/69 (23.1%) | 8/44 (18.2%) | 6/18 (33.3%) | 15/26 (57.7%) | 8/12 (66.7%) | 5/11 (45.4%) | 11/37 (29.7%) | 2/11 (18.2%) | 10/20 (50%) | 9/17 (52.9%) | 0/6 |
APACHE II predicted mortality | 21.9% | 30.1% | 24.8% | NA | 38.9% | NA |